Is the latest Alzheimer’s drug for real? Is three a crowd in CAR-T? And what’s a Bionomy?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, medicinal chemist Derek Lowe joins us to discuss China’s surprising decision to approve a new treatment for Alzheimer’s disease — and why the resulting hope quickly turned to skepticism among experts. Then, we preview an all-important FDA meeting about Amarin and it’s fish-oil-derived cardiovascular drug. Later, we talk about how Celgene might find itself on the outside looking in when it comes to CAR-T cancer therapy. Finally, in honor of STAT’s fourth birthday, executive editor Rick Berke joins us to discuss the publication’s origins and where it’s headed.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email firstname.lastname@example.org.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at email@example.com.